In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...
A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity who were taking the drug were able to shed more than a fifth of their ...
After hours: 7:59:01 p.m. EST ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
Novo Pharmaceuticals PVT LTD is an Indian Non-Government Company. It's a private company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 5.0 lakhs and has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback